Sagent To Acquire Other Half Of Kanghong Sagent JV For $25 Million
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Sagent Pharmaceuticals said it plans to acquire all of China's Kanghong Sagent Pharmaceutical in a buyout estimated at $25 million and make the company a subsidiary.
U.S.-based Sagent Pharmaceuticals said it plans to acquire all of China's Kanghong Sagent Pharmaceutical in a buyout estimated at $25 million and make the company a subsidiary. Chengdu Kanghong Pharmaceuticals and Sagent created the targeted pharma as a joint venture in 2006, each investor owning a 50% interest. Kanghong Sagent built a drug-making plant in China that meets the highest international standards and Sagent said it plans to use the acquisition, expected to be completed in September 2015, to invest more in developing products and expanding capacity. (Click here for more
)
"Sagent Assumes Control Of Chinese Manufacturing JV" - Genetic Engineering & Biotechnology News (U.S.) (5/6/2013)